Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation

Platelets play a central role in the pathogenesis of atherothrombosis. Thus, achieving platelet inhibition is an important part of managing patients that have experienced an atherothrombotic event. Dual antiplatelet therapy with clopidogrel plus aspirin has been shown to markedly reduce ischemic events in patients undergoing percutaneous coronary intervention (PCI) and stenting. Despite its proven benefit of dual antiplatelet therapy, diabetic patients remain at increased risk of recurrent ischemic events when compared to non-diabetic patients.